Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome

[1]  M. Zhang,et al.  Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome , 2021, Journal of clinical and translational hepatology.

[2]  X. Zou,et al.  Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt , 2021, Hepatology International.

[3]  G. Lin,et al.  Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans , 2020, Archives of toxicology.

[4]  G. Lin,et al.  Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China , 2020, Acta Pharmacologica Sinica.

[5]  Lingling Meng,et al.  Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study , 2020, BMC Gastroenterology.

[6]  K. Baumgartner,et al.  Cirrhosis: Diagnosis and Management. , 2019, American family physician.

[7]  Xiaofeng Zhang,et al.  Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study , 2019, European journal of gastroenterology & hepatology.

[8]  Qian Li,et al.  Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes , 2019, World journal of gastroenterology.

[9]  Y. Fei,et al.  Efficacy of transjugular intrahepatic portosystemic shunt in the treatment of 21 patients with gynura segetum-related hepatic sinusoidal obstruction syndrome , 2019 .

[10]  Jianming Xu,et al.  Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome , 2019, Journal of gastroenterology and hepatology.

[11]  Lai Wei,et al.  Chinese guidelines on the management of ascites and its related complications in cirrhosis , 2019, Hepatology International.

[12]  Ya Li,et al.  Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study , 2018, BMC Gastroenterology.

[13]  X. Zou,et al.  Clinical characteristics and treatment of pyrrolizidine alkaloid‐related hepatic vein occlusive disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[14]  I. Tabbara,et al.  Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances. , 2018, Anticancer research.

[15]  P. Wouters,et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. , 2017, European journal of anaesthesiology.

[16]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[17]  G. Lin,et al.  Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome , 2015, Drug design, development and therapy.

[18]  G. Tarantino,et al.  Tusanqi-Related Sinusoidal Obstruction Syndrome in China , 2015, Medicine.

[19]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[20]  N. Chao.  How I treat sinusoidal obstruction syndrome. , 2014, Blood.

[21]  Andrew D. Rosenberg,et al.  Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on perioperative blood transfusion and adjuvant therapies , 2006 .

[22]  Jeffrey L. Apfelbaum,et al.  Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies , 2006, Anesthesiology.